Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics

Journal Article · · Journal of Translational Medicine
Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region where multiple lysine residues, posing significant challenges for bottom-up proteomics analysis of the SPOP mutations. To address this issue, PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing)-SRM (selected reaction monitoring) mass spectrometry assays have been developed for quantifying wild-type SPOP protein and 11 prostate cancer-derived SPOP mutations. Despite inherent limitations due to amino acid sequence constraints, all the PRISM-SRM assays developed using Arg-C digestion showed a linear dynamic range of at least two orders of magnitude, with limits of quantification range from 0.1 to 1 fmol/μg of total protein in the cell lysate. Applying these SRM assays to analyze HEK293T cells with and without expression of the three most frequent SPOP mutations in prostate cancer (Y87N, F102C or F133V) led to confident detection of all three SPOP mutations in corresponding positive cell lines but not in the negative cell lines. Expression of the F133V mutation and wild-type SPOP was at much lower levels compared to that of F102C and Y87N mutations; however, at present it is unknown if this also affects the activity of the SPOP protein. In summary, PRISM-SRM enables multiplexed, isoform-specific detection of mutant SPOP proteins in cell lysates, which holds great potential in biomarker development for prostate cancer.
Research Organization:
Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
Sponsoring Organization:
National Institutes of Health (NIH); USDOE
Grant/Contract Number:
AC05-76RL01830
OSTI ID:
1406773
Alternate ID(s):
OSTI ID: 1757986
Report Number(s):
PNNL-SA--125993; 49639; 453040220
Journal Information:
Journal of Translational Medicine, Journal Name: Journal of Translational Medicine Journal Issue: 1 Vol. 15; ISSN 1479-5876
Publisher:
BioMed Central Ltd.Copyright Statement
Country of Publication:
United States
Language:
English

References (38)

Current trends in quantitative proteomics journal January 2009
An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity journal May 2012
Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present journal July 2012
Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype journal September 2014
The emerging role of speckle-type POZ protein (SPOP) in cancer development journal September 2014
Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer journal November 2014
Sensitive Targeted Quantification of ERK Phosphorylation Dynamics and Stoichiometry in Human Cells without Affinity Enrichment journal December 2014
Mass Spectrometric Quantitation of Peptides and Proteins Using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) journal April 2004
Targeted Quantification of Low ng/mL Level Proteins in Human Serum without Immunoaffinity Depletion journal June 2013
A Highly Sensitive Targeted Mass Spectrometric Assay for Quantification of AGR2 Protein in Human Urine and Serum journal December 2013
Mutant proteins as cancer-specific biomarkers journal January 2011
Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum journal September 2012
Correction for Geng et al., Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover journal June 2019
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods journal January 2015
SPOP the mutation journal October 2015
Less label, more free: Approaches in label-free quantitative mass spectrometry journal January 2011
The Molecular Taxonomy of Primary Prostate Cancer journal November 2015
Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants journal February 2014
Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins journal February 2013
Re: The Molecular Taxonomy of Primary Prostate Cancer journal June 2016
Targeted proteomic strategy for clinical biomarker discovery journal December 2008
GeLC-MRM Quantitation of Mutant KRAS Oncoprotein in Complex Biological Samples journal June 2012
Spectral Probabilities and Generating Functions of Tandem Mass Spectra: A Strike against Decoy Databases journal August 2008
The cancer genome journal April 2009
MS-GF+ makes progress towards a universal database search tool for proteomics journal October 2014
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer journal May 2012
SCISSOR: a framework for identifying structural changes in RNA transcripts journal January 2021
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover journal April 2013
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments journal February 2010
The path to routine use of genomic biomarkers in the cancer clinic journal October 2015
Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer journal October 2014
Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer journal September 2014
The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification journal December 2015
SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts journal January 2014
The Molecular Taxonomy of Primary Prostate Cancer text January 2015
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer text January 2012
SPOP mutations in prostate cancer across demographically diverse patient cohorts text January 2014
SPOP mutation leads to genomic instability in prostate cancer journal September 2015

Cited By (1)

Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer journal November 2017


Similar Records

Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation
Journal Article · Sun Jan 22 19:00:00 EST 2023 · Molecular Cell · OSTI ID:2425479

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods
Journal Article · Wed Dec 31 19:00:00 EST 2014 · Journal of Translational Medicine · OSTI ID:1184918